A Phase 4 interventional study of Ranolazine and Ranolazine placebo in Angina Pectoris, Coronary Artery Disease and Type 2 Diabetes Mellitus, sponsored by Gilead Sciences. Completed at 135 sites in 14 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-11-04.
Sponsored by Gilead Sciences · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies testing ranolazine in Angina Pectoris — none open to participants now, none under way, none of them phase 3. Ranolazine · Angina Pectoris.
Among the 14 studies testing ranolazine in Angina Pectoris, this one is the 3rd largest by enrollment, is one of 4 that started in 2011, is one of 5 in phase 4, and was the 7th registered.
454 studies on the registry are indexed under Angina Pectoris; 68 are open to participants now.
Browse Angina Pectoris studies →None of the 14 studies testing ranolazine in Angina Pectoris is open now. The open studies under Angina Pectoris, anywhere →
Ranolazine: first FDA approval 2006 (RANEXA), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →
Of the 47 Angina Pectoris studies recruiting now, 35 (74%) set no upper age limit and 1 (2%) stops at 75 or younger; 3 take children under 18; 5 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 4 started in 2011.
This study's enrollment of 949 is above the median of 100 across 273 interventional studies indexed under Angina Pectoris.
Median enrollment 44 across the 14 interventional studies. Of the 10 that completed or were terminated, 7 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 14 have an industry lead sponsor. The 9 most frequent:
Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.
Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.
Gilead Sciences has 7 studies filed under Angina Pectoris — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 14 studies testing ranolazine in Angina Pectoris, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will evaluate the effect of ranolazine compared to placebo on the average weekly angina frequency in subjects with chronic stable angina and coronary artery disease (CAD) who have a history of type 2 diabetes mellitus (T2DM), and whether ranolazine can reduce the frequency of angina (chest pain) attacks, compared to a placebo. Subjects will be asked to record their daily angina episodes in a diary at the end of each study day. Ranolazine is approved for the treatment of chronic angina, and is not approved for the treatment of T2DM.
Participants who meet the eligibility criteria at screening will enter a 4-to 6-week Qualifying Period. The allowed concomitant antianginal medication(s) must be maintained at a stable dose throughout the study. Participants will document the number of angina episodes, number of sublingual nitroglycerin doses taken, and a dyspnea score (on a scale from 1 to 5) on a daily basis in a diary. Participants eligible to stay in the study after the Qualifying Period will enter the 8-week double-blind dosing phase. Participants will have study visits at the end of Weeks 2 and 8. Participants will continue to document the number of angina episodes and number of sublingual nitroglycerin doses taken as well as a dyspnea score on a daily basis by the end of each day in their diary. In addition, participants will be called during Week 2 and at the end of Week 5 to encourage compliance. A safety follow-up phone call will be made 14 days after the last study visit or early discontinuation.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
CAD documented by one or more of the following:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Qualifying phase: Participants will enter a 2-week washout period if needing to discontinue antianginal drugs (except beta-blockers) followed by placebo to match ranolazine (1 tablet twice daily) during a 4-week run-in period. Participants with at least 85% adherence to documentation requirements (angina frequency and sublingual nitroglycerin use) over the last 21 days of the placebo run-in period will be randomized to the treatment period. Treatment Period: Placebo to match ranolazine (Day 1: 1 tablet in the evening; Days 2-7: 1 tablet twice daily; 2 tablets twice daily thereafter) for up to 8 weeks.
Drug: Ranolazine placebo
Qualifying phase: Participants will enter a 2-week washout period if needing to discontinue antianginal drugs (except beta-blockers) followed by placebo to match ranolazine (1 tablet twice daily) during a 4-week run-in period. Participants with at least 85% adherence to documentation requirements (angina frequency and sublingual nitroglycerin use) over the last 21 days of the placebo run-in period will be randomized to the treatment period. Treatment period: Ranolazine tablets (Day 1: 1 × 500 tablet in the evening; Days 2-7: 1 × 500 mg twice daily; 2 × 500 mg twice daily thereafter) for up to 8 weeks.
Drug: Ranolazine · Drug: Ranolazine placebo
Also known as: Ranexa®
Average Weekly Angina Frequency Over the Last 6 Weeks of Treatment
Average weekly angina frequency was defined as the total number of angina episodes reported during the last 6 weeks of treatment divided by 6 weeks. For subjects who terminated with less than 6 weeks of treatment, frequency was calculated as the total number of angina episodes reported during the treatment period divided by the subject's actual duration of treatment.
Time frame: 6 weeks
Average Weekly Frequency of Sublingual Nitroglycerin Use Over the Last 6 Weeks of Treatment
Average weekly frequency of sublingual nitroglycerin use was defined as the total number reported during the last 6 weeks of treatment divided by the duration corresponding to the last 6 weeks of treatment.
Time frame: 6 weeks
Percentage of Weeks Participants Achieved at Least a 50% Reduction in Angina Frequency
For each participant, the percentage of the last 6 weeks on treatment during which the angina frequency was less than or equal to 50% of the baseline average weekly angina frequency was determined.
Time frame: 6 weeks
Percentage of the Last 6 Weeks on Treatment During Which the Angina Frequency Was ≤ 50% of the Baseline Average Weekly Angina Frequency
Time frame: 6 weeks
Change From Baseline in the Short-Form 36® (SF-36) Mental and Physical Component Scores
The range of each health domain score is 0-100, with 0 indicating a poorer health state and 100 indicating a better health state. An increase in score indicates an improvement in health state. Participants were asked to complete the survey at randomization (prior to receiving treatment), and at end of treatment visit (Week 8) or early study drug discontinuation or early termination visit. The survey asked participants for responses specific to the preceding 4 weeks prior to completing the survey.
Time frame: Up to 8 weeks
Patient's Global Impression of Change (PGIC) Scale Score
The PGIC was completed at the end of treatment/last visit.The PGIC scale measures the change in the participant's overall status since the beginning of the study on a scale ranging from 1 (no change or worse) to 7 (very much improved).
Time frame: 8 weeks
Participants were enrolled at a total of 116 study sites in North America, Europe, and Asia. The first participant was screened on 05 October 2011. The last participant observation occurred on 25 October 2012.
| Milestone | Placebo | Ranolazine |
|---|---|---|
| Started | 476 | 473 |
| Completed | 457 | 451 |
| Not completed | 19 | 22 |
| Withdrew: Randomized but not treated | 2 | 3 |
| Withdrew: Adverse event | 9 | 8 |
| Withdrew: Revascularization | 0 | 1 |
| Withdrew: Death | 0 | 1 |
| Withdrew: Unsatisfactory response | 1 | 0 |
| Withdrew: Protocol violation | 1 | 2 |
| Withdrew: Subject withdrew consent | 1 | 2 |
| Withdrew: Investigator's discretion | 2 | 0 |
| Withdrew: Did not meet qualifying criteria | 3 | 5 |
Average weekly angina frequency was defined as the total number of angina episodes reported during the last 6 weeks of treatment divided by 6 weeks. For subjects who terminated with less than 6 weeks of treatment, frequency was calculated as the total number of angina episodes reported during the treatment period divided by the subject's actual duration of treatment.
| angina attacks per week | Placebo | Ranolazine |
|---|---|---|
| Average Weekly Angina Frequency Over the Last 6 Weeks of Treatment | 5.2 ± 4.73 | 4.5 ± 4.32 |
Average weekly frequency of sublingual nitroglycerin use was defined as the total number reported during the last 6 weeks of treatment divided by the duration corresponding to the last 6 weeks of treatment.
| nitroglycerin uses per week | Placebo | Ranolazine |
|---|---|---|
| Average Weekly Frequency of Sublingual Nitroglycerin Use Over the Last 6 Weeks of Treatment | 3.6 ± 5.35 | 2.9 ± 4.34 |
For each participant, the percentage of the last 6 weeks on treatment during which the angina frequency was less than or equal to 50% of the baseline average weekly angina frequency was determined.
| percentage of weeks | Placebo | Ranolazine |
|---|---|---|
| Percentage of Weeks Participants Achieved at Least a 50% Reduction in Angina Frequency | 41 ± 36 | 46 ± 35 |
| percentage of weeks | Placebo | Ranolazine |
|---|---|---|
| Percentage of the Last 6 Weeks on Treatment During Which the Angina Frequency Was ≤ 50% of the Baseline Average Weekly Angina Frequency | 50 ± 1.4 | 54 ± 1.3 |
The range of each health domain score is 0-100, with 0 indicating a poorer health state and 100 indicating a better health state. An increase in score indicates an improvement in health state. Participants were asked to complete the survey at randomization (prior to receiving treatment), and at end of treatment visit (Week 8) or early study drug discontinuation or early termination visit. The survey asked participants for responses specific to the preceding 4 weeks prior to completing the survey.
| units on a scale | Placebo | Qualifying Phase: Participants Entered a 2-week Washout Period |
|---|---|---|
| Mental Component Score | 1.2 ± 0.37 | 1.0 ± 0.39 |
| Physical Component Score | 1.9 ± 0.25 | 2.8 ± 0.26 |
The PGIC was completed at the end of treatment/last visit.The PGIC scale measures the change in the participant's overall status since the beginning of the study on a scale ranging from 1 (no change or worse) to 7 (very much improved).
| units on a scale | Placebo | Ranolazine |
|---|---|---|
| Patient's Global Impression of Change (PGIC) Scale Score | 3.9 ± 0.07 | 4.0 ± 0.07 |
Collected over Baseline to Day 56 plus 30 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 20/474 (4.2%) | 0/474 (0%) |
| Ranolazine | — | 16/470 (3.4%) | 0/470 (0%) |
| Event | Placebo | Ranolazine |
|---|---|---|
| Angina unstableCardiac disorders | 1/474 | 3/470 |
| Acute myocardial infarctionCardiac disorders | 3/474 | 2/470 |
| Atrial fibrillationCardiac disorders | 3/474 | 0/470 |
| Ischaemic strokeNervous system disorders | 3/474 | 1/470 |
| Chest painGeneral disorders | 1/474 | 2/470 |
| Cardiac failure acuteCardiac disorders | 2/474 | 0/470 |
| Angina pectorisCardiac disorders | 1/474 | 1/470 |
| Cardiac failure chronicCardiac disorders | 0/474 | 1/470 |
| Cardiogenic shockCardiac disorders | 0/474 | 1/470 |
| Ventricular tachycardiaCardiac disorders | 0/474 | 1/470 |
Safety Analysis Set: randomized participants who received at least one dose of study treatment.
| Age, Continuous(years) | Placebo | Ranolazine | Total |
|---|---|---|---|
| Mean | 64 ± 8.5 | 63 ± 8.6 | 64 ± 8.5 |
| Age, Customized(participants) | Placebo | Ranolazine | Total |
|---|---|---|---|
| < 65 years | 249 | 264 | 513 |
| 65 - 74 years | 170 | 160 | 330 |
| ≥ 75 years | 55 | 46 | 101 |
| Sex: Female, Male(Participants) | Placebo | Ranolazine | Total |
|---|---|---|---|
| Female | 182 | 180 | 362 |
| Male | 292 | 290 | 582 |
| Race/Ethnicity, Customized(participants) | Placebo | Ranolazine | Total |
|---|---|---|---|
| Asian | 1 | 1 | 2 |
| Black or African American | 2 | 5 | 7 |
| White | 471 | 464 | 935 |
| Race/Ethnicity, Customized(participants) | Placebo | Ranolazine | Total |
|---|---|---|---|
| Hispanic or Latino | 5 | 4 | 9 |
| Not Hispanic or Latino | 464 | 462 | 926 |
| Not Reported | 3 | 3 | 6 |
| Unknown | 2 | 1 | 3 |
| Region of Enrollment(participants) | Placebo | Ranolazine | Total |
|---|---|---|---|
| United States | 12 | 15 | 27 |
| Belarus | 1 | 0 | 1 |
| Serbia | 3 | 2 | 5 |
| Slovenia | 0 | 1 | 1 |
| Slovakia | 12 | 9 | 21 |
| Ukraine | 53 | 69 | 122 |
| Israel | 10 | 14 | 24 |
| Russian Federation | 281 | 263 | 544 |
| Czech Republic | 3 | 6 | 9 |
| Canada | 2 | 1 | 3 |
| Poland | 53 | 40 | 93 |
| Bulgaria | 9 | 11 | 20 |
| Georgia | 36 | 40 | 76 |
| Germany | 1 | 2 | 3 |
| Body Mass Index(kg/m^2) | Placebo | Ranolazine | Total |
|---|---|---|---|
| Mean | 31.1 ± 4.90 | 31.3 ± 5.01 | 31.2 ± 4.96 |
| Glycosylated hemoglobin (HbA1c)(percent HbA1c in blood) | Placebo | Ranolazine | Total |
|---|---|---|---|
| Mean | 7.3 ± 1.53 | 7.3 ± 1.50 | 7.3 ± 1.52 |
Showing the first 100 of 135 sites across 14 countries. Choose a country and city above to see the rest.
The record gives a start of Sep 2011, a primary completion of Oct 2012 and a completion of Oct 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2014, 2 years 1 month after primary completion. A results delay was requested in Oct 2013.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ranolazine